GLP-1 Slows Hypoglycemia-Induced Gastric Emptying
In healthy subjects, GLP-1 attenuates accelerated gastric emptying and glucose absorption
THURSDAY, April 17, 2014 (HealthDay News) -- For healthy subjects, exogenous glucagon-like peptide 1 (GLP-1) attenuates hypoglycemia-induced acceleration of gastric emptying, according to a study published online March 5 in Diabetes Care.
Mark P. Plummer, M.D., from the University of Adelaide in Australia, and colleagues examined whether GLP-1 attenuates hypoglycemia-induced acceleration of gastric emptying. Ten healthy subjects received intravenous GLP-1 or placebo during hypoglycemia and euglycemia. At time 0, subjects ingested beef mince labeled with 99mTc-sulfur-colloid and a marker of glucose absorption (3-O-methyl-glucose [OMG]). Gastric emptying was measured scintigraphically through 180 minutes and 3-OMG was sampled at 15-minute intervals.
The researchers found that gastric emptying and glucose absorption were accelerated during hypoglycemia (hypoglycemia/placebo versus euglycemia/placebo; P < 0.001 and P < 0.03, respectively). During euglycemia, GLP-1 slowed gastric emptying (euglycemia/placebo versus euglycemia/GLP-1; P < 0.001). GLP-1 diminished hypoglycemia-induced acceleration of gastric emptying (hypoglycemia/placebo versus hypoglycemia/GLP-1; P < 0.008) and glucose absorption (P < 0.01).
"Acute administration of exogenous GLP-1 attenuates, but does not abolish, the acceleration of gastric emptying by insulin-induced hypoglycemia in healthy subjects," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.